CABS 2021 INVESTOR FORUM

  • January 13, 2021
  • 4:00 PM - 7:40 PM
  • Online Zoom conference (register on Zoom below)

Registration

Chinese American Biopharmaceutical Society (CABS) is proud to present 2021 Investor Forum at 4-7:30 pm PST on January 13, 2021, in conjunction with the JP Morgan Healthcare Conference. 

The Investor Forum will be joined by 16 China- and US-based investors, business development executives, and entrepreneurs. The topics will focus on the trends, opportunities and challenges in capital investment, business development and M&A, next generation of innovative therapeutics. The impact of COVID-19 and US-China relationship on Biopharma investment will also be discussed. The Investor Forum will be from 4 pm to 7:40pm.

  • 3 Panel Discussions; 16 High-Profile Guest Panelists
  • Next Wave of Innovative Therapies
  • Trends of Capital Raising in Biotech and Pharma
  • Building Cross-border Life Science Companies
  • Join at 4PM: Networking and Socializing over Zoom
  • Stay Until the End: Meet with Panelists over Zoom


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND

Please Update to to Latest Version of Zoom (click here to update) before Join-in. Otherwise You Cannot Use Zoom Breakout Room Function.


Agenda (Based on US Pacific Time)

4-4:50 pm: Networking in Zoom Breakrooms

4:55-5:00 pm: Opening remarks by Yang Tian, CABS President

5-5:50 pm Investor Forum Panel 1: Invest in Next Generation of Innovative Therapeutics

Moderator: Janet Xiao, Partner, Morrison & Foerster LLP

Panelists: Jennifer Goldstein, Managing Partner, Silicon Valley Bank

Nick Naclerio, Founding Partner, Illumina Ventures

Vincent Xiang, Founder and Managing Partner, 7G Bioventure

Michael Salgaller, Supervisory Specialist, Invention Development and Marketing, NIH

Howard Edelman, CEO, SeeMedX

5:50-6:30 pm Investor Forum Panel 2: Trends of Capital Raising in Biotech and Pharma

Moderator: Alex Zhang, CEO, Hanhai Silicon Valley

Panelists: Cherry Lu, Founding and Managing Partner, RedHill Capital

Thomas Chou, Partner, Morrison & Foerster LLP

Michael Chan, Head of International Issuer Services, Hong Kong Stock Exchange

Helen Chen, Greater China Managing Partner, Head of China Life Sciences, L.E.K. Consulting

6:30-7:10 pm Investor Forum Panel 3: Building Cross-border Life Sciences Companies: Challenges and Opportunities

Moderator: Cheni Kwok, Managing Partner and Founder, Linear Dreams

Panelists: Cynthia Cai, Venture Partner, Viva BioInnovator

Bin Li, Founder and CEO, Lake Bleu Capital

Hai Mi, Managing Partner, Panacea Venture

Scott Liu, Co-founder and Head of Strategic Advisory Committee, Henlius Biotech

7:10-7:40pm Meet with Panelists on Zoom

7:40pm End of event


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND


Investor Forum Panelists


Janet Xiao, PhD, JD, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term.  

Jennifer Goldstein, Partner, Silicon Valley Bank

Jennifer Goldstein is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of Venture Forward, a non-profit that provides resources and education towards developing a diverse, equitable, and inclusive venture ecosystem. She is also an advisory board member of Springboard Enterprises and the Women’s Health Innovation Coalition. A bioengineer by training, Jennifer is passionate about the role that venture investing can bring to discovery in the fields of health care and life sciences. She is currently leading SVB Capital’s Life Science & Healthcare investment team and helping develop the bank’s first life science direct investment fund for institutional Limited Partners. Jennifer has more than 20 years of experience in the venture and startup market segments, including leading and building several teams over the past 8 years at Silicon Valley Bank. Prior to that, she was a director on Pfizer's Venture Capital team, where she helped lead or co-lead investments into several life sciences companies, led fund-of-fund investment decisions, and independently managed Pfizer’s $250 million private equity portfolio. Jennifer has also served as a consultant on private equity deals across Europe while at Bain & Company and has held operational and research roles at Chiron, Genelabs, and Genencor. Jennifer graduated magna cum laude with a BSE in Bioengineering and a Master's of Biotechnology from the University of Pennsylvania. She holds an MBA from the Wharton School, where she was named a Joseph Wharton Fellow. She also serves as an independent director at Alexandria Real Estate Equities, Inc.

Nick Naclerio, PhD, Founding Partner, Illumina Ventures

Nick is the Founding Partner of Illumina Ventures. His passion is building companies at the intersection of technology and human health. Prior to joining the fund, he served as SVP, Corporate & Venture Development for Illumina where he was responsible for strategic planning, business development, licensing, venture investing and acquisitions. In six years, Nick and his team completed ten acquisitions, more than a dozen venture investments, and a multitude of other transactions including the formation of Helix and GRAIL and the creation of a global NIPT patent pool. Nick also served as the founding General Manager of Illumina’s Enterprise Informatics Business Unit. Before joining Illumina, Nick co-founded and was the Executive Chairman of the diagnostics company Quanterix. Previously he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. Nick got his start in venture investing at Motorola where he led the life science investment team and served on the boards of the SNP Consortium, Genometrix, Clinical Microsensors, and Orchid Bioscience. He founded and led Motorola Life Sciences, an early microarray company that was acquired by GE. Previously he held leadership positions at DARPA and served on the board of SEMATCH. Nick is chairman of Serimmune and Stilla Technologies, and also serves on the boards of Baebies, Cradle Genomics, DNA Script, Genome Medical, LetsGetChecked and Pattern Bioscience. Nick received a B.S. in Engineering from Duke University, was a Winston Churchill Scholar at Cambridge University, and earned a Ph.D. in Electrical Engineering from the University of Maryland.

Vincent Xiang, PhD, Founding and Managing Partner, 7G BioVentures

Dr. Xiang has worked in the life sciences industry for more than 20 years, with rich experience in scientific research, product development, company management, investment and mergers and acquisitions. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm in 2016. Dr. Xiang has comprehensive practical experiences in leading and managing top fund investment and financing business for many years, and has a deep understanding of the capital market. The pursuit of excellence in clinical data and his extensive industry network make him a well-known investment expert in the field of international pharmaceutical investment and financing. From 2018 to 2020, Dr. Xiang was Head of BioVenture at Hillhouse Capital with responsibilities of global venture capital investment, team building, procedures determination, decision making for investment projects. He personally led 9 investment projects ranging from series A round to crossover round while his team invested 31 projects successfully. From 2016 to 2018, Dr. Xiang was the partner at 6 Dimensions Capital, which is a leading healthcare focused investment firm with an in- depth focus and extensive coverage across China and the United States.  He led 8 projects and those 8 projects had been successfully set up in next round or already went IPO. He was awarded the best performance partner in investing achievements in 6 Dimensions. Prior to 2016, he worked as Managing Director and Head of international investments & business development at Humanwell Healthcare Group, Managing Director of Burrill Life Science Venture Capital Fund, Portfolio Manager/Analyst at Franklin Templeton. Dr. Xiang began his career at Sinopharm in China. Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.

Michael Salgaller, PhD, Supervisory Specialist of Invention Development and Marketing Unit, National Cancer Institute Technology Transfer Center

Dr. Michael Salgaller leads the Invention Development and Marketing Unit (IDMU) within the National Cancer Institute’s Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support licensing and technology development partnerships. The IDMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NIH. He is a long-time industry executive who held various positions in boutique professional service and early-stage biotechnology firms – as well as several years in government affairs and on the investment team of a venture capital firm dedicated to the life sciences. He is the author of “Biotechnology Entrepreneurship,” and teaches an entrepreneurship class at NIH. He is on the Board of Canines-N-Kids, a foundation supporting cooperation between researchers in pediatric and veterinary oncology. He has written over 100 articles, presentations, and book chapters. Dr. Salgaller received his PhD in Pathology from The Ohio State University.

Howard Edelman, Chairman of the Medical Device and Digital Health Screening Committee, Life Science Angels, CEO of SeedMedX

Howard Edelman is a medical device executive accomplished in all phases of medical product development and operations in a variety of organizational structures. Most recently, Mr. Edelman was General Manager of Cothera, a division of United Orthopedic Group, a global orthopedic company which provides medical devices and patient services into the secondary orthopedic market. Cothera was recently purchased by Breg in November of 2014. Previously, Howard Edelman was the Founder and CEO of VitalWear, a leader in thermal therapy. In 2009, VitalWear was named on the INC 500 list of fastest growing private companies and on the San Francisco Business Times Fast 100. In 2010, Medical Device & Diagnostic Industry listed VitalWear as one of the top 50 medical device companies to watch. Mr. Edelman has served in management roles in firms such as Johnson & Johnson, Zeiss, CooperVision, and Bio-Rad Laboratories and various startup companies in the Bay Area. Mr. Edelman is a member of the BayBio Expert Network and sat on the Research Committee for the Juvenile Diabetes Research Foundation. Mr. Edelman holds a B.S. in Biomedical Engineering from Boston University.

Alex Zhang, PhD, MBA, CEO of Hanhai Silicon Valley

Alex Zhang is the CEO of Hanhai Silicon Valley., an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents. Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as the President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.        

Cherry Lu, Funding and Managing Partner, RedHill Capital

Experienced Partner with a demonstrated history of working in the leading venture capital and healthcare industry. Strong business development professional graduated from The Chinese University of Hong Kong and Tongji Medical Academy of Huazhong Science & Technology University. The details are as follow:– 13 years at Sequoia Capital China, from analyst to partner in Sequoia’s history – Led investment in 30+ MedTech/Biotech companies and many of them has become sub-segment leaders, e.g. Jafron (300529, a leading enterprise in China blood purification industry), Snibe (300832, IVD), Winner Medical (300888), Iray(688301), Armo (ARMO, Nasdaq), XtalpI(Industry pacesetter), etc. – Industry recognition: Forbes 2020 Top 25 Female Venture Capitalists in China; Forbes 2018 Top 25 Female Venture Capitalists in China; Instructor for Merck China Innovation Center; FMBA instructor at Cheung Kong Graduate School of Business

Thomas Chou, Partner, Morrison & Foerster

Thomas Chou is a co-head of the firm’s Asia private equity practice and a leader in the firm’s China M&A practice, both of which are consistently highly ranked in major independent industry league tables and lawyer ranking organizations. Thomas’ corporate practice spans over two decades of experience in the U.S. and Asia Pacific region, focusing on cross-border mergers and acquisitions (inbound and outbound), joint ventures, as well as private equity and venture capital financings. His clients include industry leading growth companies as well the investors who fund them (private equity and venture capital funds, family offices, corporate/strategic investment arms of MNCs, insurance companies, and sovereign wealth funds). His practice is focused on the healthcare and life sciences, technology, media and telecom, and consumer and retail industries. He is ranked as a leading individual in China for Corporate/M&A and Private Equity: Buyouts & Venture Capital Investment  by Chambers Asia-Pacific 2020. He is also a leading individual for Private Equity and is highly recommended for Healthcare and Life Sciences by Legal 500 Asia-Pacific 2020. His clients pinpoint his “decades of venture capital experience both in the United States and in Asia,” with one noting: “He is patient, attentive to details and someone who has clearly conquered many battlefields.”

Michael Chan, Head of International Issuer Services, HKEX

Mr. Michael Chan, Head of International Issuer Services, leads the international IPO and issuer marketing efforts for HKEX. Mr. Chan is mainly focused on market development work promoting the Hong Kong listing platform and origination work attracting international and biotechnology companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr. Chan often speaks and serves as panelist and keynote speaker at major conferences and events locally and internationally. Prior to his current role, Mr. Chan has worked at the Listing Division of HKEX for 8 years covering areas of compliance, corporate governance, regulatory and IPO-related matters. Prior to joining HKEX, Mr. Chanhas worked at various financial institutions in corporate finance and business development. Michael has more than 18 years of experience in financial services and regulatory work.

Helen ChenGreater China Managing Partner, Head of China Life Sciences, L.E.K. Consulting

Helen Chen is the Greater China managing partner of L.E.K. Consulting based in Shanghai, and a winner of the prestigious Global Leaders in Consulting for 2019 award from Consulting Magazine.  She sat on L.E.K.’s Global Leadership Team, the firm’s governing board, from 2012 to 2016, and served as the head of L.E.K.’s China practice from 2011 to 2018 and Asia life sciences practice from 2015 to 2019. Helen has over 30 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000. Helen is the head of L.E.K.’s China healthcare practice and a board member of L.E.K.’s Asia Pacific Life Sciences Centre of Excellence, supported by Singapore’s Economic Development Board.  She has extensive case work and industry experience covering the full biopharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness.  In China, she has developed commercial strategies for international biopharmas and medtechs, investment thesis for financial investors, business plans for domestic startups and policy analyses for industry associations. Helen is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences, and has been quoted by publications including BioCentury, BioWorld, In Vivo, Wall Street Journal, South China Morning Post, Financial Times and Forbes AsiaPrior to joining L.E.K., Helen was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now AbbVie).  She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997. Helenreceived her A.B. cum laude in applied mathematics from Harvard University.

Cheni Kwok PhD, CLP, Managing Partner and Founder, Linear Dreams

Dr. Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm’s engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation services for 45 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore. As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc..

Bin Li, PhD, Founder and CEO, Lake Bleu Capital

Dr. Bin Li is the founder and CIO of Lake Bleu Capital, an Asian healthcare investment firm based in Hong Kong and Shanghai. Previously, he was a Partner at Ally Bridge Group and prior to that he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he had been ranked as the top analyst in China healthcare industry by the most widely recognized investor surveys, including: No. 1 Asia Healthcare Analyst by the Institutional Investor (II) for seven consecutive years (2008-2014); No.1 China Healthcare Analyst each year by II since the poll started in 2010 (2010- 2014); No. 1 in Wall Street Journal's “Best Asia Healthcare Analysts” in 2010 for his stock selectionNo. 1 Asia Healthcare Analyst by other independent investor surveys including Greenwich and AsiamoneyBefore joining Morgan Stanley, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong in 2007, he was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Dr. Li has over 20-year experience in healthcare industry. He received his Ph.D. in biochemistry and MBA from New York University and bachelor’s degree in chemistry from Fudan University, China. Prior to his sell-side career, he worked at Merck Research Laboratory as a scientist and published papers on peer-reviewed science journals.

Cynthia Cai, PhD, MBA, M. Eng, President, Tharton Consulting; Venture Partner, Viva BioInnovator; Senior Advisor, Northern Light Venture Capital 

Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in healthcare and life science industry. International experience in sales, marketing, business development, and equity investment.  In-depth understanding of global biotech and life science business, widely recognized as having a unique ability to bridge collaborations between technology and business, between the west and east culture. Currently, Dr. Cai is an investor targeting early-stage opportunities of innovation and disruptive technology in healthcare field. Prior to that, Dr. Cai had over 20 years of experience in leadership positions with one of the world’s most respected life science companies. As senior director of marketing in Agilent Technologies, she was responsible for its billion-dollar Chromatography, automation and Mass Spec. business. As business development manager and product marketing manager, Dr. Cai was involved in multiple acquisitions and divestitures, also led a $500+ million-dollar flagship product development and its global commercialization. Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her Ph.D. in Chemistry from the University of Massachusetts, and MBA from The Wharton Business School of the University of Pennsylvania. She served as Delaware governor economic advisor, a member of the Board of the Forum for Executive Women (FEW-DE). She has also been a mentor for Wharton EMBA, Tsinghua University Global MBA and Drexel LeBow School of Business for many years. Dr. Cai had been a regular speaker at healthcare conferences such as BIO; RESI; China Focus at J.P. Morgan, SAPA Annual Conference and Wharton China Business Forum.

Hai Mi, PhD, Managing Partner, Panacea Venture

Dr. Hai Mi is a Founding and Managing Partner of Panacea Venture. Prior to Panacea Venture, a life science VC focuses on early-stage investment and incubation, Hai joined Kleiner Perkins Caufield & Byers China as a Partner in 2015 and focuses on the firm’s life sciences practice. Prior to joining KPCB China, Hai was a partner at DT Capital responsible for investment in life science, healthcare and other related fields. Hai was a venture partner of SB China Venture Capital (SBCVC) and his investment transactions include BGI, SyMap Medical and Precise Light.  Hai was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi Pharma Tech (NYSE: WX) in Shanghai where he played an important role in NYSE listing, and the acquisition of AppTec in US.  He also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee, and he participated in the privatization of Chemspec.  Earlier Hai was a research scientist at Pfizer in the US. Hai obtained a PhD in Organic Chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in Material Science from Fudan University in Shanghai.

Scott Liu, PhD, Co-founder and Head of Strategic Advisory Committee, Henlius Biotech

Dr. Scott Liu, the co-founder and Head of Strategic Advisory Committee at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb “Technical Operations Presidential Award” in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND

Please Update to to Latest Version of Zoom (click here to update) before Join-in. Otherwise You Cannot Use Zoom Breakout Room Function.